In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stryker Cormet Hip Resurfacing Gains FDA Approval, Will Debut By September

This article was originally published in The Gray Sheet

Executive Summary

Stryker will begin training surgeons on Corin Group's Cormet hip resurfacing system within the next three months in anticipation of a U.S. launch by the end of September, the firms say

You may also be interested in...



Hospital Suppliers Show Vigor In ’07, With Prospects Strong For ’08 – Index

Baxter and Becton Dickinson were among large-cap hospital supply firms to prove that boring can be beautiful in 2007, as med-tech investors turned off by volatility in the sexier cardiac implant sector turned on to the relative stability of diversified, low-risk hospital products with respectable growth

Hospital Suppliers Show Vigor In ’07, With Prospects Strong For ’08 – Index

Baxter and Becton Dickinson were among large-cap hospital supply firms to prove that boring can be beautiful in 2007, as med-tech investors turned off by volatility in the sexier cardiac implant sector turned on to the relative stability of diversified, low-risk hospital products with respectable growth

Zimmer Cites Lack Of Hip Resurfacing System As Drag On Growth

Zimmer's sales of total artificial hips are being constrained by competition from less invasive hip resurfacing procedures, while knee sales are being pinched by slower-than-expected adoption of the Gender Solutions knee, the firm says

Related Content

UsernamePublicRestriction

Register

MT025006

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel